C-BYOJGenescient
evolutionary genomics, selective screening, Drosophila
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BYOJ
C-BYOJC-BYOJevolutionary genomics, selective screening, Drosophila
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Genescient evolutionary genomics, selective screening, Drosophila
Genescient combines evolutionary genomics with massive selective screening to analyze and exploit the genetics of model animal and human whole genomes. The company uses its Methuselah flies and fruit-fly longevity research to inform drug development. Its stated goal is to develop novel therapeutics that target chronic diseases of aging.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Genescient — Early mechanism · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic